Update on Monogenic Diabetes in Korea

Article information

Diabetes Metab J. 2020;44(5):627-639
Publication date (electronic) : 2020 October 21
doi : https://doi.org/10.4093/dmj.2020.0214
1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
2Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea
3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
4Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University College of Medicine, Seoul, Korea
Corresponding author: Kyong Soo Park Department of Internal Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea E-mail: kspark@snu.ac.kr
Received 2020 August 26; Accepted 2020 September 6.


Monogenic diabetes, including maturity-onset diabetes of the young, neonatal diabetes, and other rare forms of diabetes, results from a single gene mutation. It has been estimated to represent around 1% to 6% of all diabetes. With the advances in genome sequencing technology, it is possible to diagnose more monogenic diabetes cases than ever before. In Korea, 11 studies have identified several monogenic diabetes cases, using Sanger sequencing and whole exome sequencing since 2001. The recent largest study, using targeted exome panel sequencing, found a molecular diagnosis rate of 21.1% for monogenic diabetes in clinically suspected patients. Mutations in glucokinase (GCK), hepatocyte nuclear factor 1α (HNF1A), and HNF4A were most commonly found. Genetic diagnosis of monogenic diabetes is important as it determines the therapeutic approach required for patients and helps to identify affected family members. However, there are still many challenges, which include a lack of simple clinical criterion for selecting patients for genetic testing, difficulties in interpreting the genetic test results, and high costs for genetic testing. In this review, we will discuss the latest updates on monogenic diabetes in Korea, and suggest an algorithm to screen patients for genetic testing. The genetic tests and non-genetic markers for accurate diagnosis of monogenic diabetes will be also reviewed.


Monogenic diabetes is a rare form of diabetes specifically caused by a single gene mutation. It includes maturity-onset diabetes of the young (MODY), neonatal diabetes, maternally inherited diabetes and deafness (MIDD), and so on. The genes causing monogenic diabetes play an important role in the development or function of pancreatic β-cells, with some exceptions of genes involved in obesity or insulin resistance. Patients with monogenic diabetes are characterized by early-onset diabetes and a family history of diabetes in multiple first-degree relatives. Monogenic diabetes is frequently misdiagnosed as either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Accurate molecular genetic diagnosis of monogenic diabetes is crucial because the therapeutic approach can be directed by the causative gene in some cases and it helps to identify affected family members.

Among the different types of monogenic diabetes, MODY is the most common form. It is a clinically heterogeneous group of disorders characterized by β-cell dysfunction, causing earlyonset diabetes with autosomal dominant inheritance. Genetic mutations associated with MODY have been reported in 14 genes, to date, as shown in Table 1 [1,2]. There has been a continuous effort to identify and characterize patients with MODY in Korea since 2001. However, some limitations faced were methods for genetic testing, lack of experienced labs, and no referral system focusing on monogenic diabetes. Consequently, it has been difficult to estimate the prevalence of MODY in Korean patients with diabetes and what the most common form of MODY is.

Related genes and associated clinical characteristics and treatments of MODYs

Over the past decade, there has been a substantial advancement in genome sequencing technology. Next generation sequencing (NGS) based whole exome or targeted panel sequencing is now widely used not only for research purposes but also for the clinical molecular diagnosis of monogenic diabetes. A few recent reports on monogenic diabetes in Korea also rely on these methods. Compared to the conventional Sanger sequencing, targeted panel sequencing has higher sensitivity with higher sequencing depth and improved throughput with the ability to sequence hundreds of genes simultaneously. The number of cases with genetically confirmed monogenic diabetes is increasing and a new era of diagnosis and treatment of monogenic diabetes has emerged. However, clinicians still question the criteria for genetic testing and the interpretation of the sequencing results. It is also not known whether there are different characteristics of monogenic diabetes in East Asians compared to other ethnicities.

In this review, we discuss the latest updates on monogenic diabetes, primarily focusing on MODY in the Korean population. In addition, we suggest an algorithm that could help clinicians diagnose different types of monogenic diabetes based on clinical clues. Finally, genetic tests and non-genetic markers for the accurate diagnosis of monogenic diabetes are discussed.


Since MODY was first described by Tattersall [3] in 1974, several advanced genetic studies have been conducted. A majority of the large-scale genetic studies were performed in Europeans. In two German studies which involved 40,927 and 2,064 patients who were diagnosed with diabetes before the age of 25 years and had been treated successfully with diet changes or oral drugs for 5 years, the prevalence of MODY was estimated to be 0.14% and 1.8%, respectively [4,5]. In another German/Austrian cohort of 40,757 patients <20 years of age, 0.83% was identified as MODY by clinical criteria [6]. According to the largest and most comprehensive study in the UK in which genetic tests for monogenic diabetes were used [7], the prevalence of MODY was estimated to be at least 1.08%. In the study, the genetic diagnosis rate was 27% (567/2,072), and hepatocyte nuclear factor 1α (HNF1A) (52%) and glucokinase (GCK) (32%) were the most common mutations followed by HNF4α (HMF4A; 10%) and HNF1β (HNF1B; 6%). A recently published report based on a nationwide population-based registry of Norway showed that a total of 6.5% of autoantibody-negative child patients had genetic variants of MODY confirmed by NGS [8].

In comparison to studies on European population, the studies establishing the prevalence and genetic diagnosis rate of monogenic diabetes in Asian population are quite few [9-12]. In a Chinese study, the prevalence of HNF1A- and GCK-MODY in 146 unrelated MODY families was 9% and 1%, respectively [9]. A recent study on 82 autoantibody-negative Chinese patients who were clinically diagnosed with T1DM, showed that 22% had mutations related to monogenic diabetes and up to 6% of Chinese have monogenic diabetes [12]. HNF1A was the most common form (6/18, 33%), however, there were a number of recessive mutations of Wolfram syndrome 1 (WFS1) [12]. An analysis of South Asians in the UK revealed that the genetic diagnosis rate was 12.6% [10]. Among 263 Japanese patients with suspected MODY, 39.2% had one of the four MODY gene mutations—GCK, HNF1A, HNF4A, and HNF1B— when tested with Sanger sequencing, and 21.6% had a GCK mutation [13]. Molecular diagnosis rate in Koreans was 21.1% for patients with clinically suspected monogenic diabetes and 1.1% for patients with overall non-T1DM in the recent largest study [14]. The most common form of MODY was GCK (50%), followed by HNF1A (21.4%) and HNF4A (21.4%).

It is not clear whether MODY prevalence and its subtype frequency differ in ethnic groups. Most of the large-scale studies were conducted in Europeans, hence further studies on different populations are needed. In addition, population-based screening using uniform criteria or universal screening is required to compare prevalence or subtype frequency between different populations. Clinical criteria to screen patients for genetic testing may affect not only the MODY subtype frequency [15] but also the sensitivity in differentiating MODY from early-onset T2DM [10]. As Korean patients with diabetes have lower body mass index (BMI) at diagnosis of diabetes and tend to have earlier onset of diabetes compared to Europeans [16,17], these factors should be considered when interpreting the results. In this context, recent Korean studies suggest BMI ≥27.5 kg/m2 as a threshold for exclusion for genetic tests because none of the participants with BMI ≥27.5 kg/m2 had suggestive pathogenic variants for MODY [14], even though a cut-off based on diagnostic performance was not discerned.

The MODY subtype frequency also varies among studies on the same ethnic group. This is because the results are influenced by the study designs, such as cut-off age determined, genetic testing method used, and whether subjects are limited to cases of strong suspicion or include all cases of early-onset diabetes. In addition, the clinical suspicion rate is relatively low in some subtypes when it is asymptomatic or due to its benign nature as in the case of GCK-MODY. Therefore, an accurate assessment of prevalence and subtype frequency is possible only if diagnosis using genetic and non-genetic tests is performed on a large-scale population based on sufficient suspicion of monogenic diabetes.


In Korea, the first genetic study on MODY was conducted in 2001. It focused on the HNF1A gene, however, there was only one silent mutation among 69 early-onset T2DM cases (1/69, 1.5%) [18]. During the period of 2003 to 2008, there have been several approaches for the detection of HNF1A mutations in clinically suspected MODY patients and early-onset diabetes. Kim et al. [19] detected a R263L missense mutation using direct sequencing in one patient among 16 early-onset T2DM cases (1/16, 6.3%). Their functional studies revealed that the mutation was associated with decreased insulin production and defective glucose sensing [19]. In one study on 17 children with T2DM and their families, a mutation of the promoter of HNF1A (1/22, 4.5%) was found in a child’s mother, who was diagnosed with diabetes as an adult [20]. In other studies, around 5% of the population was detected to have genetic mutations in HNF1A; 5.0% (2/40) of 23 MODY and 17 early-onset T2DM cases using direct sequencing [21], 4.0% (1/25) of 25 early-onset T2DM cases using DNA chip [22] and 5.2% (5/96) of 96 gestational diabetes mellitus (GDM) cases using direct sequencing [23]. Other MODY mutations were reported less frequently on using direct sequencing; one mutation of GCK [21], HNF4A [21], and HNF1B [24], respectively.

Since 2015, studies using whole exome sequencing (WES) have been conducted on Korean subjects. Shim et al. [25] did not find any known disease-causing alleles of MODY; however, they reported three candidate gene variants in PTPRD, SYT9, and WFS1 found in six MODY probands and their families. In another early-onset diabetes population, four pathogenic or likely pathogenic missense variants in HNF4A, HNF1A, and ABCC8 were found using WES [26]. In the case of WES for three patients with clinical signs of GCK-MODY, two missense mutations in GCK were found [27].

Recently an approach to detect and evaluate the pathogenic variants using targeted panel sequencing was reported by Park et al. [14]. On genetic testing of 109 suspected monogenic diabetes candidates among 2,090 patients with non-T1DM, using the panel including the exonic and untranslated regions of 30 genes known to cause monogenic diabetes, 14 pathogenic/likely pathogenic variants of common MODY genes were identified. However, 78% of patients did not have a molecular genetic diagnosis, which suggested that the other causes of MODY, such as MODYX may not have been analyzed. The studies on monogenic diabetes in Korean subjects to date are summarized in Table 2.

Studies for monogenic diabetes in Korean subjects


The summary of the clinical characteristics and treatment of MODY to date is described in Table 1. The pathophysiology and clinical characteristics of the most common types of MODY: GCK-MODY, HNF1A-MODY, and HNF4A-MODY—are described below. More specific information about each MODY subtype, including the more rare ones, is available in recent review articles [1,28].


GCK, the β-cell glucose sensor, is a key enzyme that catalyzes glucose to glucose-6-phosphate and controls glucose-mediated insulin secretion. Heterozygous inactivating mutations in GCK gene cause GCK-MODY. More than 600 mutations in more than 1,000 families have been identified and these lead to both hypoglycemia and hyperglycemia [29]. People with GCK-MODY show mild fasting hyperglycemia (5.6 to 8.0 mmol/L, HbA1c range 5.6% to 7.3%) [30], because they have a problem with glucose sensing and their glucose homeostasis is set at a higher range. Patients are usually asymptomatic, so the majority are discovered by routine examinations during pregnancy or school-based urine glucose screening tests. In very rare conditions, a complete deficiency of GCK is reported as permanent neonatal diabetes [31]. In GCK-MODY, microvascular complications [32] are rare and macrovascular complications [33] are similar to those in the general population. Treatment is not recommended except in the case of pregnancy, because glucose-lowering therapy is ineffective [34] and there is a lack of long-term complications. However, it should be noted that T2DM can coexist with GCK-MODY and may be a major risk factor for further morbidities [35]. In pregnancy, fetal growth is determined by whether the mutation is inherited [36]. If the fetus does not inherit the mutation, it will sense the maternal glucose as high and increase insulin secretion which results in increased birth weight. Thus, insulin treatment of the mother is required when fetal overgrowth is detected on fetal growth scans. Since the management of hyperglycemia during pregnancy and after delivery could be altered according to the diagnosis of GCK-MODY, genetic testing should be considered when the GCK mutation is suspected in a woman with GDM (Fig. 1).

Fig. 1.

Approach that recommends genetic testing based on clinical clues suspected of monogenic diabetes. MODY, maturity-onset diabetes of young; HNF4B, hepatocyte nuclear factor 4B; MIDD, maternally inherited diabetes and deafness; WFS, Wolfram syndrome; GCK, glucokinase.


HNF1A, a homeodomain-containing transcription factor, is expressed in the pancreatic β-cells, kidney, liver, and intestine. HNF1A knockout mice develop diabetes because of impaired β-cell response to glucose [37], and also have an abnormal architecture of pancreatic islet [38]. HNF1A is a polymorphic gene without any specified mutation hot-spot [39], and more than 400 different variants have been identified [40]. HNF1A mutations demonstrate high penetrance; 63% of carriers develop diabetes by the age of 25, and almost all of the carriers develop diabetes by the age of 55 [41]. Hyperglycemia induced by heterozygous HNF1A mutations might be severe and progressive, and the risk of long-term micro and macrovascular complications is similar to that of T1DM and T2DM [42]. As patients with HNF1A-MODY show marked sensitivity to sulfonylurea [43-45], low-dose sulfonylurea is recommended as the first-line treatment. In an observational study, 79% of patients could be switched to sulfonylurea from insulin therapy after the correct genetic diagnosis of MODY [46]. Although some patients eventually took insulin treatment, the majority of patients maintained good glycemic control for many years with sulfonylurea [46].


HNF4A is a transcription factor that is expressed in the liver, intestine, kidney, and pancreatic islets. It regulates genes that are essential to glucose transport and metabolism [47]. More than 100 mutations of HNF4A have been identified so far [40]. The clinical nature of progressive β-cell dysfunction and response to sulfonylureas in heterozygous HNF4A mutations are similar to HNF1A-MODY [48]. Heterozygous HNF4A mutations are associated with significant fetal macrosomia due to increased insulin secretion in utero and the hyperinsulinemia results in neonatal hypoglycemia and diabetes later in life [49]. Therefore, close monitoring of the offspring of an affected mother is recommended in patients with HNF4A-MODY.


Candidates for genetic testing: who should have genetic testing for monogenic diabetes?

As NGS-based targeted panel sequencing is readily available, genetic screening is expected to be performed in more cases. However, additional costs for genetic testing are present, and interpretation of the sequence results remains an issue. The clinical criteria for genetic testing for MODY are not well established [50,51], and there are no concrete cutoff values for the age of diagnosis and BMI. Therefore, clinicians should consider who would be the best candidate for genetic testing for MODY.

Guidelines [52] were established in 2008 by European clinicians and scientists for clinical suspicion of diabetes caused by mutations in the GCK, HNF1A, and HNF4A genes, which are the most common forms of MODY. The clinician’s suspicion for MODY should arise from the atypical features of T1DM and T2DM in childhood, adolescence, or young adulthood [52,53]. Features atypical for T1DM are as follows [54]: absence of pancreatic islet autoantibodies [55], measurable C-peptide in the presence of hyperglycemia [56,57], low insulin requirement for treatment and lack of diabetic ketoacidosis. Features atypical for T2DM include lack of insulin resistance and metabolic syndrome [58,59], young-onset before <45 years, normal weight or mildly overweight, and less frequent insulin use [59]. There are at least five generally accepted diagnostic criteria for MODY [60]: (1) age at diagnosis <25 years in at least one family member; (2) autosomal dominant inheritance across three generations; (3) absence of insulin therapy within 5 years of diagnosis; (4) insulin level within the normal range (plasma insulin ≥2.0 μIU/mL or plasma C-peptide ≥0.6 ng/mL); and (5) not obese (BMI <25 kg/m2).

One suggestive modality for selecting the candidate for the genetic test is the MODY probability calculator [61] which is available online (https://www.diabetesgenes.org/mody-probability-calculator/). It uses eight pieces of clinical information and shows improved sensitivity (91% vs. 72%) and specificity (94% vs. 91%) for detecting MODY compared to standard clinical criteria including diagnosis of patients under 25 years and family history [61]. Although the prediction models were derived from the logistic regression of data on Europeans mostly, it validated that Korean MODY patients showed a significantly high probability [14] as shown in UK patients [62].

Fig. 1 shows an algorithm that recommends genetic testing based on clinical clues suggesting monogenic diabetes. If the onset of diabetes is within the first 6 months of life, genetic testing for neonatal diabetes should be conducted because T1DM usually occurs after then. Genetic tests for MODY should be conducted when a clinician encounters T1DM or T2DM patients with atypical features as mentioned above: (1) the absence of pancreatic autoantibodies and measurable C-peptide levels in T1DM, and (2) the absence of insulin resistance and family history of diabetes in at least one individual aged ≤25 years in at least two generations. When a urogenital anomaly is accompanied in a situation where MODY is suspected, it may be helpful to conduct targeted testing for the HNF4B mutation [63]. In addition, there are some specific clinical features for other rare monogenic diabetes. In the case of MIDD, a rare mitochondrial disorder caused by a genetic mutation in transfer RNA, patients have both a defect in insulin secretion and sensorineural hearing loss [64]. Another syndromic disorder, WFS comes with diabetes insipidus, diabetes mellitus, optic atrophy, and sensorineural deafness [65]. When a subject has hearing difficulty, MIDD or WFS could be the cause. Patients with GCK-MODY show mild fasting hyperglycemia and are usually asymptomatic. As the majority of patients are discovered on routine examinations during pregnancy, woman with diagnosed GDM who have family history of diabetes or persistent diabetes after delivery could have GCK-MODY.

How to interpret the genetic test result

Depending on the target region size, sequencing usually identifies a large number of coding variants in the gene of interest. It is crucial to discern whether the identified variant is the true pathogenic variant or just a bystander. One of the good starting points would be to lookup the variant in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/). This is a public database that archives the relationship between a specific genetic variant and disease status. The pathogenicity of the variant and its evidence are submitted by the provider and reviewed by expert panels. If the identified variant is novel, it should be evaluated for its pathogenicity. Recently the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) [66] has published guidelines for the interpretation of sequence variants to improve the efficacy of clinical genetics. The ACMG-AMP guideline classifies variants as pathogenic, likely pathogenic, variant with uncertain significance, likely benign, and benign. The evidence attributes are derived from population allele frequency, computational prediction, functional studies, segregation analysis, allelic data, etc. Population allele frequency serves as an important criterion to filter out pathogenic variants. This information could be obtained from a genome aggregation database (gnomAD, https://gnomad.broadinstitute.org/), which also includes the allele frequency in Koreans. However, it would be important to have a larger database for Korean specific allele frequency and also to archive variants that are associated with monogenic diabetes.

Non-genetic biomarkers for MODY

There have been many efforts to discover non-genetic biomarkers to improve the diagnosis rate of MODY with efficient and cheap methods [67]. The approach using biomarkers is expected to provide additional clinical suspicions of MODY and narrow down candidates for molecular testing. Among the suggested biomarkers so far, high-sensitivity C-reactive protein (hs-CRP) has emerged as a novel biomarker after the association between the alteration in hs-CRP levels and common variants in HNF1A was reported with genome-wide association studies (GWAS) [68,69]. The level of hs-CRP was significantly lower in HNF1A-MODY patients than in any other group—T1DM, T2DM, GCK-MODY, and normal glucose-tolerant participants—in several studies of the European population [70-73]. Because hs-CRP has been widely used in many clinical settings, it would be a cost-effective screening test to discriminate HNF1A-MODY from other types of diabetes when combined with current clinical diagnosis. However, the cutoff values for differential diagnosis are not well established [70,72]. Additionally, there are controversial results regarding Asian ethnicities because of various factors, such as BMI and race influence on the level of hs-CRP. In a Japanese HNF1A-MODY patient, the serum hs-CRP level was lower than that observed in T1DM and T2DM [74]. A study in Singapore which mostly involved Chinese and Indian races did not show improvement in the diagnostic yield with the hs-CRP criteria (1/37, 2.7%) when compared with the traditional clinical criteria (5/125, 4%) [75]. Thus, the efficacy of hs-CRP as a diagnostic criterion and the appropriate cutoff values for clinical feasibility, especially in the Asian population need to be elucidated.

In addition to hs-CRP, plasma fucosylated glycans is a promising candidate for an HNF1A diagnostic marker [73,76]. A study combining GWAS and glycomics analysis revealed that HNF1A regulates multiple steps in fucosylation [77] which affects N-glycan levels in humans. The discriminative performance of both total plasma N-glycome and some glycan groups showed higher power with area under the curves, at least more than 0.87, in distinguishing patients with damaging HNF1A alleles from those without risk alleles [73]. Apolipoprotein M (apoM), a lipoprotein that is associated with the high-density lipoprotein particle is another protein encoded by a gene for which HNF1A acts as a transcriptional activator. Serum apoM level was lower in the HNF1A-MODY group compared with the control participants [78] and the T1DM group [79]. However, a subsequent study could not replicate the result [80], and only women with HNF1A mutations had 10% lower serum apoM levels compared with controls in another study [81]. Due to a variety of techniques and subject identifications used for analysis, discrepancies could be observed between studies using biomarkers. Further work and standard techniques are needed to investigate the role of apoM as a useful biomarker for HNF1A-MODY.

Recently microRNAs (miRNAs) have emerged as potential regulators of gene functions associated with diabetes [82-84]; therefore, approaches using miRNAs as biomarkers for differentiating MODY from other types of diabetes have been used in vivo [85,86] and in vitro [87]. Although the miRNAs should be verified in large population studies in order to be used as biomarkers in a clinical setting, if miRNAs are involved in the pathophysiology of MODY and its antagomirs can be used to correct pathognomonic pathways, they can be used as therapeutic targets for MODY.


Monogenic diabetes in Asians is estimated to represent around 1 to 6% of all diabetes cases. In Korea, there have been 11 studies to date which focused on identifying monogenic diabetes. In the recent largest study in 2019 using targeted exome panel sequencing, a molecular diagnosis rate was 21.1% for monogenic diabetes in clinically suspected patients. As the study design influences the prevalence and genetic diagnosis rate, the definite prevalence and difference due to ethnicity could not be concluded. For further established results, it is necessary to conduct a pan-Asian registration and a joint research to accumulate MODY frequency and allele frequency data for Asians. The most important step in the diagnosis of monogenic diabetes is to identify candidates for the genetic test. The physician should be familiar with the clinical clues of monogenic diabetes and have a clear understanding of fundamental principles for interpreting the results. The suggestive algorithm and non-genetic tools could help the diagnostic approach.



No potential conflict of interest relevant to this article was reported.




1. Kim SH. Maturity-onset diabetes of the young: what do clinicians need to know? Diabetes Metab J 2015;39:468–77.
2. Urakami T. Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment. Diabetes Metab Syndr Obes 2019;12:1047–56.
3. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43:339–57.
4. Panzram G, Adolph W. Heterogeneity of maturity onset diabetes at young age (MODY). Lancet 1981;2:986.
5. Ledermann HM. Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? Lancet 1995;345:648.
6. Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T, Holl RW, ; DPV-Wiss Initiative of the German Working Group for Paediatric Diabetology and. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009;26:466–73.
7. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504–8.
8. Johansson BB, Irgens HU, Molnes J, Sztromwasser P, Aukrust I, Juliusson PB, Sovik O, Levy S, Skrivarhaug T, Joner G, Molven A, Johansson S, Njolstad PR. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia 2017;60:625–35.
9. Xu JY, Dan QH, Chan V, Wat NM, Tam S, Tiu SC, Lee KF, Siu SC, Tsang MW, Fung LM, Chan KW, Lam KS. Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients. Eur J Hum Genet 2005;13:422–7.
10. Misra S, Shields B, Colclough K, Johnston DG, Oliver NS, Ellard S, Hattersley AT. South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people. Diabetologia 2016;59:2262–5.
11. Kanthimathi S, Jahnavi S, Balamurugan K, Ranjani H, Sonya J, Goswami S, Chowdhury S, Mohan V, Radha V. Glucokinase gene mutations (MODY 2) in Asian Indians. Diabetes Technol Ther 2014;16:180–5.
12. Li M, Wang S, Xu K, Chen Y, Fu Q, Gu Y, Shi Y, Zhang M, Sun M, Chen H, Han X, Li Y, Tang Z, Cai L, Li Z, Shi Y, Yang T, Polychronakos C. High prevalence of a monogenic cause in Han Chinese diagnosed with type 1 diabetes, partly driven by nonsyndromic recessive WFS1 mutations. Diabetes 2020;69:121–6.
13. Yorifuji T, Higuchi S, Kawakita R, Hosokawa Y, Aoyama T, Murakami A, Kawae Y, Hatake K, Nagasaka H, Tamagawa N. Genetic basis of early-onset, maturity-onset diabetes of the young-like diabetes in Japan and features of patients without mutations in the major MODY genes: Dominance of maternal inheritance. Pediatr Diabetes 2018;19:1164–72.
14. Park SS, Jang SS, Ahn CH, Kim JH, Jung HS, Cho YM, Lee YA, Shin CH, Chae JH, Kim JH, Choi SH, Jang HC, Bae JC, Won JC, Kim SH, Kim JI, Kwak SH, Park KS. Identifying pathogenic variants of monogenic diabetes using targeted panel sequencing in an East Asian population. J Clin Endocrinol Metab 2019;jc.2018-02397.
15. Yorifuji T, Fujimaru R, Hosokawa Y, Tamagawa N, Shiozaki M, Aizu K, Jinno K, Maruo Y, Nagasaka H, Tajima T, Kobayashi K, Urakami T. Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes 2012;13:26–32.
16. Rhee EJ. Diabetes in Asians. Endocrinol Metab (Seoul) 2015;30:263–9.
17. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375:408–18.
18. Lee HJ, Ahn CW, Kim SJ, Song YD, Lim SK, Kim KR, Lee HC, Huh KB. Mutation in hepatocyte nuclear factor-1alpha is not a common cause of MODY and early-onset type 2 diabetes in Korea. Acta Diabetol 2001;38:123–7.
19. Kim KA, Kang K, Chi YI, Chang I, Lee MK, Kim KW, Shoelson SE, Lee MS. Identification and functional characterization of a novel mutation of hepatocyte nuclear factor-1alpha gene in a Korean family with MODY3. Diabetologia 2003;46:721–7.
20. Choi IK, Kim DH, Kim HS, Huh N, Paek SH, Jung SY. The prevalence of Maturity Onset Diabetes of the Young (MODY) 3 in children with type 2 diabetes mellitus. Korean J Pediatr 2004;47:641–6.
21. Hwang JS, Shin CH, Yang SW, Jung SY, Huh N. Genetic and clinical characteristics of Korean maturity-onset diabetes of the young (MODY) patients. Diabetes Res Clin Pract 2006;74:75–81.
22. Lim DM, Huh N, Park KY. Hepatocyte nuclear factor 1-alpha mutation in normal glucose-tolerant subjects and early-onset type 2 diabetic patients. Korean J Intern Med 2008;23:165–9.
23. Kim HS, Hwang SH, Choi ES, Park SY, Yim CH, Han KO, Yoon HK, Chung HY, Kim KS, Bok J, Lee JY, Kim SH. Mutation screening of HNF-1alpha gene in Korean women with gestational diabetes mellitus. Korean Diabetes J 2008;32:38–43.
24. Kim EK, Lee JS, Cheong HI, Chung SS, Kwak SH, Park KS. Identification and functional characterization of P159L mutation in HNF1B in a family with Maturity-Onset Diabetes of the Young 5 (MODY5). Genomics Inform 2014;12:240–6.
25. Shim YJ, Kim JE, Hwang SK, Choi BS, Choi BH, Cho EM, Jang KM, Ko CW. Identification of candidate gene variants in Korean MODY families by whole-exome sequencing. Horm Res Paediatr 2015;83:242–51.
26. Kwak SH, Jung CH, Ahn CH, Park J, Chae J, Jung HS, Cho YM, Lee DH, Kim JI, Park KS. Clinical whole exome sequencing in early onset diabetes patients. Diabetes Res Clin Pract 2016;122:71–7.
27. Cho EH, Min JW, Choi SS, Choi HS, Kim SW. Identification of maturity-onset diabetes of the young caused by glucokinase mutations detected using whole-exome sequencing. Endocrinol Metab (Seoul) 2017;32:296–301.
28. Jang KM. Maturity-onset diabetes of the young: update and perspectives on diagnosis and treatment. Yeungnam Univ J Med 2020;37:13–21.
29. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S, Gloyn AL. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30:1512–26.
30. Steele AM, Wensley KJ, Ellard S, Murphy R, Shepherd M, Colclough K, Hattersley AT, Shields BM. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One 2013;8e65326.
31. Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, Undlien DE, Shiota C, Magnuson MA, Molven A, Matschinsky FM, Bell GI. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001;344:1588–92.
32. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014;311:279–86.
33. Fendler W, Rizzo M, Borowiec M, Malachowska B, Antosik K, Szadkowska A, Banach M, Urbanska-Kosinska M, Szopa M, Malecki M, Mlynarski W. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol 2014;51:625–32.
34. Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, Hattersley AT. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014;57:54–6.
35. Stanik J, Kusekova M, Huckova M, Valentinova L, Masindova I, Stanikova D, Ferenczova J, Gasperikova D, Klimes I. Impact of type 2 diabetes on glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family: case report. Endocr Regul 2012;46:99–105.
36. Spyer G, Macleod KM, Shepherd M, Ellard S, Hattersley AT. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 2009;26:14–8.
37. Pontoglio M, Sreenan S, Roe M, Pugh W, Ostrega D, Doyen A, Pick AJ, Baldwin A, Velho G, Froguel P, Levisetti M, Bonner-Weir S, Bell GI, Yaniv M, Polonsky KS. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest 1998;101:2215–22.
38. Yamagata K, Nammo T, Moriwaki M, Ihara A, Iizuka K, Yang Q, Satoh T, Li M, Uenaka R, Okita K, Iwahashi H, Zhu Q, Cao Y, Imagawa A, Tochino Y, Hanafusa T, Miyagawa J, Matsuzawa Y. Overexpression of dominant-negative mutant hepatocyte nuclear fctor-1 alpha in pancreatic beta-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced beta-cell proliferation, and diabetes. Diabetes 2002;51:114–23.
39. Valkovicova T, Skopkova M, Stanik J, Gasperikova D. Novel insights into genetics and clinics of the HNF1A-MODY. Endocr Regul 2019;53:110–34.
40. Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat 2013;34:669–85.
41. Shepherd M, Ellis I, Ahmad AM, Todd PJ, Bowen-Jones D, Mannion G, Ellard S, Sparkes AC, Hattersley AT. Predictive genetic testing in maturity-onset diabetes of the young (MODY). Diabet Med 2001;18:417–21.
42. Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010;27:157–61.
43. Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993;16:1254–61.
44. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000;17:543–5.
45. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275–81.
46. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009;26:437–41.
47. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 1997;94:13209–14.
48. Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ, Wierzbicki AS, Clark PM, Lebl J, Pedersen O, Ellard S, Hansen T, Hattersley AT. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 2005;48:878–85.
49. Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007;4e118.
50. Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011;75:422–6.
51. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011;343:d6044.
52. Ellard S, Bellanne-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008;51:546–53.
53. Hattersley AT, Greeley SA, Polak M, Rubio-Cabezas O, Njolstad PR, Mlynarski W, Castano L, Carlsson A, Raile K, Chi DV, Ellard S, Craig ME. ISPAD Clinical Practice Consensus Guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2018;19 Suppl 27:47–63.
54. Shields BM, Shepherd M, Hudson M, McDonald TJ, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson ER, Hattersley AT; UNITED study team. Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care 2017;40:1017–25.
55. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, Williams A, Hattersley AT, Ellard S. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med 2011;28:1028–33.
56. Ludvigsson J, Carlsson A, Forsander G, Ivarsson S, Kockum I, Lernmark A, Lindblad B, Marcus C, Samuelsson U. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2012;13:45–50.
57. Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34:286–91.
58. Owen KR, Stride A, Ellard S, Hattersley AT. Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. Diabetes Care 2003;26:2088–93.
59. Owen KR, Shepherd M, Stride A, Ellard S, Hattersley AT. Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics. Diabet Med 2002;19:758–61.
60. Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev 2008;29:254–64.
61. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012;55:1265–72.
62. Thomas ER, Brackenridge A, Kidd J, Kariyawasam D, Carroll P, Colclough K, Ellard S. Diagnosis of monogenic diabetes: 10-year experience in a large multi-ethnic diabetes center. J Diabetes Investig 2016;7:332–7.
63. Bellanne-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, Clauin S, Beaufils S, Wilhelm JM, Boitard C, Noel LH, Velho G, Timsit J. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 2004;140:510–7.
64. Donovan LE, Severin NE. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol Metab 2006;91:4737–42.
65. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995;346:1458–63.
66. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.
67. Owen KR, Skupien J, Malecki MT, ; CEED3 Consortium. The clinical application of non-genetic biomarkers for differential diagnosis of monogenic diabetes. Diabetes Res Clin Pract 2009;86 Suppl 1:S15–21.
68. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI, Walston JD, Cooper GM, Jenny NS, Rieder MJ, Durda JP, Smith JD, Novembre J, Tracy RP, Rotter JI, Stephens M, Nickerson DA, Krauss RM. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008;82:1193–201.
69. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet 2008;82:1185–92.
70. Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI, Gloyn AL. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010;33:1919–24.
71. McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, Hattersley AT. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011;34:1860–2.
72. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D, Szopa M, Tjora E, James TJ, Kokko P, Loiseleur F, Andersson E, Gaget S, Isomaa B, Nowak N, Raeder H, Stanik J, Njolstad PR, Malecki MT, Klimes I, Groop L, Pedersen O, Froguel P, McCarthy MI, Gloyn AL, Owen KR. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 2011;54:2801–10.
73. Juszczak A, Pavic T, Vuckovic F, Bennett AJ, Shah N, Pape Medvidovic E, Groves CJ, Sekerija M, Chandler K, Burrows C, Rojnic Putarek N, Vucic Lovrencic M, Cuca Knezevic J, James TJ, Gloyn AL, Lauc G, McCarthy MI, Owen KR, Gornik O. Plasma fucosylated glycans and C-reactive protein as biomarkers of HNF1A-MODY in young adult-onset nonautoimmune diabetes. Diabetes Care 2019;42:17–26.
74. Ohki T, Utsu Y, Morita S, Karim MF, Sato Y, Yoshizawa T, Yamamura K, Yamada K, Kasayama S, Yamagata K. Low serum level of high-sensitivity C-reactive protein in a Japanese patient with maturity-onset diabetes of the young type 3 (MODY3). J Diabetes Investig 2014;5:513–6.
75. Rama Chandran S, Bhalshankar J, Farhad Vasanwala R, Zhao Y, Owen KR, Su-Lyn Gardner D. Traditional clinical criteria outperform high-sensitivity C-reactive protein for the screening of hepatic nuclear factor 1 alpha maturity-onset diabetes of the young among young Asians with diabetes. Ther Adv Endocrinol Metab 2018;9:271–82.
76. Thanabalasingham G, Huffman JE, Kattla JJ, Novokmet M, Rudan I, Gloyn AL, Hayward C, Adamczyk B, Reynolds RM, Muzinic A, Hassanali N, Pucic M, Bennett AJ, Essafi A, Polasek O, Mughal SA, Redzic I, Primorac D, Zgaga L, Kolcic I, Hansen T, Gasperikova D, Tjora E, Strachan MW, Nielsen T, Stanik J, Klimes I, Pedersen OB, Njølstad PR, Wild SH, Gyllensten U, Gornik O, Wilson JF, Hastie ND, Campbell H, McCarthy MI, Rudd PM, Owen KR, Lauc G, Wright AF. Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 2013;62:1329–37.
77. Lauc G, Essafi A, Huffman JE, Hayward C, Knezevic A, Kattla JJ, Polasek O, Gornik O, Vitart V, Abrahams JL, Pucic M, Novokmet M, Redzic I, Campbell S, Wild SH, Borovecki F, Wang W, Kolcic I, Zgaga L, Gyllensten U, Wilson JF, Wright AF, Hastie ND, Campbell H, Rudd PM, Rudan I. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet 2010;6e1001256.
78. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003;52:2989–95.
79. Mughal SA, Park R, Nowak N, Gloyn AL, Karpe F, Matile H, Malecki MT, McCarthy MI, Stoffel M, Owen KR. Apolipoprotein M can discriminate HNF1A-MODY from type 1 diabetes. Diabet Med 2013;30:246–50.
80. Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebska A, Klupa T, Wanic K, Nowak N, Borowiec M, Sieradzki J, Malecki MT. Evaluation of apolipoprotein m serum concentration as a biomarker of HNF-1alpha MODY. Rev Diabet Stud 2007;4:231–5.
81. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlback B, Karlsson E. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010;267:316–21.
82. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol 2007;5e203.
83. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R, Rutter GA, Van Obberghen E. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007;282:19575–88.
84. Poy MN, Spranger M, Stoffel M. microRNAs and the regulation of glucose and lipid metabolism. Diabetes Obes Metab 2007;9 Suppl 2:67–73.
85. Bonner C, Nyhan KC, Bacon S, Kyithar MP, Schmid J, Concannon CG, Bray IM, Stallings RL, Prehn JH, Byrne MM. Identification of circulating microRNAs in HNF1A-MODY carriers. Diabetologia 2013;56:1743–51.
86. Bacon S, Engelbrecht B, Schmid J, Pfeiffer S, Gallagher R, McCarthy A, Burke M, Concannon C, Prehn JH, Byrne MM. MicroRNA-224 is readily detectable in urine of individuals with diabetes mellitus and is a potential indicator of beta-cell demise. Genes (Basel) 2015;6:399–416.
87. Zhu Y, You W, Wang H, Li Y, Qiao N, Shi Y, Zhang C, Bleich D, Han X. MicroRNA-24/MODY gene regulatory pathway mediates pancreatic β-cell dysfunction. Diabetes 2013;62:3194–206.

Article information Continued

Fig. 1.

Approach that recommends genetic testing based on clinical clues suspected of monogenic diabetes. MODY, maturity-onset diabetes of young; HNF4B, hepatocyte nuclear factor 4B; MIDD, maternally inherited diabetes and deafness; WFS, Wolfram syndrome; GCK, glucokinase.

Table 1.

Related genes and associated clinical characteristics and treatments of MODYs

Gene Pathophysiology Clinical feature Frequency of microvascular complication Treatment
HNF4A β-cell dysfunction Macrosomia Frequent Sensitive to SU
Transient neonatal hyperinsulinemic hypoglycemia
Progressive insulin secretory defect
GCK β-cell dysfunction (glucose sensing defect) Stable mild fasting hyperglycemia at birth Rare Diet and exercise
Typically asymptomatic
HNF1A β-cell dysfunction; mainly insulin secretory defect Transient neonatal hyperinsulinemic hypoglycemia Frequent Sensitive to SU
Progressive insulin secretory defect
Renal glycosuria
PDX1 β-cell dysfunction Pancreatic agenesis Unknown Diet/OAD/insulin
Overweight/obesity in some
HNF1B β-cell dysfunction IUGR Frequent Insulin
Renal anomalies
Urogenital tract anomalies
Pancreatic hypoplasia
NEUROD1 β-cell dysfunction Homozygote: permanent neonatal diabetes and neurological abnormalities Unknown OAD/insulin
Overweight/obesity in some
KLF11 Decreased glucose sensitivity of β-cell Similar to type 2 diabetes mellitus Unknown OAD/insulin
CEL Pancreatic endocrine and exocrine dysfunction Pancreatic atrophy → exocrine pancreatic insufficiency Unknown OAD/insulin
Fibrosis & lipomatosis → diabetes
PAX4 β-cell dysfunction Possible ketoacidosis Unknown Diet/OAD/insulin
INS β-cell dysfunction Permanent neonatal diabetes Unknown Diet/OAD/insulin
BLK Insulin secretion defect Overweight/obesity in some Unknown Diet/OAD/insulin
ABCC8 ATP-sensitive potassium channel dysfunction Similar to HNF1A- and HNF4A-MODY Unknown Sensitive to SU
KCNJ11 ATP-sensitive potassium channel dysfunction Transient and permanent neonatal diabetes Unknown OAD/insulin
Overweight/obesity in some
APLL1 Insulin secretion defect Overweight/obesity in some Unknown Diet/OAD/insulin

MODY, maturity-onset diabetes of young; SU, sulfonylurea; OAD, oral antidiabetic agents; IUGR, intrauterine growth restriction.

Table 2.

Studies for monogenic diabetes in Korean subjects

Gene Methods Subjects Finding Year Reference
HNF1A SSCP technique 69 Early onset T2DM 1/69 (1.5%) Synonymous mutation 2001 [18]
HNF1A Sanger sequencing 16 Early onset T2DM 1/16 (6.25%) Nonsynonymous mutation (R263L) 2003 [19]
HNF1A DNA chip 22 Early onset T2DM 1/22 (4.5%) Promoter polymorphism, non-segregating 2004 [20]
HNF4A, GCK, HNF1A Sanger sequencing 23 MODY, 17 early onset T2DM 2/40 (5%) HNF1A (P393fsdelC, promoter) 2006 [21]
1/40 (2.5%) GCK (R191W)
1/40 (2.5%) HNF4A (T130I, polymorphism)
HNF1A DNA chip 25 Early onset T2DM 1/25 (4%) Promoter polymorphism 2008 [22]
HNF1A Sanger sequencing 96 GDM 5/96 (5.2%) 2 Promoter, Arg278Gln, Pro300pro, IVS5 +106A>G 2008 [23]
HNF1B Sanger sequencing 1 MODY P159L mutation 2014 [24]
PTPRD, SYT9, WFS1 WES 6 MODY 3 Variants (Thr207Ile in PTPRD, Gln187Glu in SYT9, Val509Gly in WFS1) 2015 [25]
HNF4A, ABCC8, HNF1A WES 28 Early onset T2DM 4 Pathogenic/likely pathogenic variants (Leu319Pro in HNF4A, His103Tyr and Arg74Gln in ABCC8, Leu139Val in HNF1A) 2016 [26]
6 Non-silent variants
GCK WES 3 Suspected MODY 2 Variants (Leu30Pro, Ser83Leu) 2017 [27]
GCK, HNF1A, HNF4A, HNF1B Targeted panel sequencing 109 Suspected monogenic diabetes 14/109 (12.8%): MODY (7 GCK, 3 HNF1A, 3 HNF4A, 1 HNF1B) 2019 [14]
5/109 (4.6%): mitochondrial MT-TL1
4/109 (3.7%): WFS1, INS, ABCC8, FOXP3

SSCP, single-strand conformation polymorphsm; T2DM, type 2 diabetes mellitus; MODY, maturity-onset diabetes of young; GDM, gestational diabetes mellitus; WES, whole exome sequencing.